LY3502970 + clarithromycin

**LY3502970 (orforglipron) + clarithromycin** is a combination of a novel oral non-peptide *glucagon-like peptide-1 receptor (GLP-1R) agonist* and the macrolide antibiotic *clarithromycin*. LY3502970 (also known as orforglipron, OWL833) is a potent, selective small-molecule partial GLP-1R agonist in clinical development for type 2 diabetes and obesity. It acts via biased agonism favoring G protein signaling, and has pharmacologic effects similar to injectable GLP-1R agonists, including glucose lowering, insulinotropic, and weight reduction effects[1][2][3][4]. Clarithromycin is a widely used oral macrolide antibiotic with activity against a variety of bacterial pathogens, indicated primarily for respiratory tract and skin infections. This specific fixed combination is not a recognized or marketed pharmaceutical product; information on the interaction or combined pharmacology is not established in the literature and should be interpreted as hypothetical or exploratory.

Brand names

orforglipron

Other names

orforglipronclarithromycin